Business
The surgery was successful: Lumenis will sell the surgical division for $ 1.07 billion
From Yokneam to Boston for $ 1 billion: An agreement has been reached on the sale of Lumnis' surgical division to the medical equipment giant Boston Scientific.
Price: Over $ 1 billion.
CEO Tzipi Ozer Armon: "This is a moment of pride for Lumenis and the entire Israeli industry"
Tags
Lumenis
Hi-Tech
medicine
Nir Kipnis
Wednesday, 03 March 2021, 16:19 Updated: 16:39
Share on Facebook
Share on WhatsApp
Share on general
Share on general
Share on Twitter
Share on Email
0 comments
Lumenis, Israel's largest medical device company, plans to sell its surgical division to global medical device giant Boston Scientific for $ 1.07 billion, subject to closure adjustments
.
Boston Scientific intends to retain the company's operations in the country and turn it into a global center of excellence for it in the field of laser technologies
.
In doing so, the division will become an integral part of Boston Scientific's urology division, and a center of excellence in the global giant's laser technology field.
Lumenis is one of the world's leading companies in the development, production and marketing of energy-based medical devices, designed for a wide range of fields, including surgical treatments, a variety of aesthetic treatments and treatments in the field of eyes and vision.
The company markets its products in dozens of countries around the world.
The company is headquartered in Yokneam and employs about 450 people in Israel (out of about 1,500 worldwide).
The division sold is the surgical division, which includes laser solutions for minimally invasive surgeries in the fields of urology, ENT and more.
Lumenis invented the laser technologies used in these fields, and over the years has continued to innovate and refine its solutions and maintain its world-leading position in the field.
The company's flagship technology, Moses ™, is a global breakthrough in urology and has demonstrated increased clinical efficacy over other solutions, as well as a significant reduction in surgical times in the treatment of kidney and urinary stones and the treatment of an enlarged prostate.
Lumenis products are used by thousands of hospitals around the world, and in recent years the company has strengthened its position as a world leader in its field, presenting growth rates above and above the market average, characterized by huge global competitors.
The sale of the surgical division is a significant strategic move not only for Lumenis, but for the Israeli Medtech industry in general.
Boston Scientific intends to keep the company's operations in the country and make it a global center of excellence for it in the field of laser technologies.
Thus, Boston Scientific will strengthen its affinity for the Israeli ecosystem and its access to the talent pool in Israel, and the company's website in Yokneam will enable the acceleration and expansion of the development of future innovative solutions.
More on Walla!
Hear well, live well: Get to know the revolutionary Oticon MORE hearing aid
To the full article
Tzipi Ozer Armon, CEO of Lumenis (Photo: Ilya Melnikov)
Israeli pride
"Boston Scientific has acquired our surgical division because it knows, like the industry as a whole, that we are leading the innovation in the field," said Tzipi Ozer Armon, CEO of Lumenis. "For us, this is a double achievement: And make Lumenis' unique technology accessible to tens of millions of other users around the world, and also allow Lumenis to focus and invest in accelerated growth in aesthetics and eye care, while implementing the company's value - Delivering Better Technology for Better Patient Care.
This is a moment of pride for Lumenis and the entire Israeli industry. "
Share on Facebook
Share on WhatsApp
Share on general
Share on general
Share on Twitter
Share on Email
0 comments